LLY

759.75

-0.52%↓

JNJ

176.59

+0.08%↑

ABBV

220.03

+1.83%↑

UNH

341.1

+0.38%↑

AZN

77.6

-0.01%↓

LLY

759.75

-0.52%↓

JNJ

176.59

+0.08%↑

ABBV

220.03

+1.83%↑

UNH

341.1

+0.38%↑

AZN

77.6

-0.01%↓

LLY

759.75

-0.52%↓

JNJ

176.59

+0.08%↑

ABBV

220.03

+1.83%↑

UNH

341.1

+0.38%↑

AZN

77.6

-0.01%↓

LLY

759.75

-0.52%↓

JNJ

176.59

+0.08%↑

ABBV

220.03

+1.83%↑

UNH

341.1

+0.38%↑

AZN

77.6

-0.01%↓

LLY

759.75

-0.52%↓

JNJ

176.59

+0.08%↑

ABBV

220.03

+1.83%↑

UNH

341.1

+0.38%↑

AZN

77.6

-0.01%↓

Search

Madrigal Pharmaceuticals Inc

Gesloten

SectorGezondheidszorg

417.52 -1.82

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

415.53

Max

429.66

Belangrijke statistieken

By Trading Economics

Inkomsten

31M

-42M

Verkoop

76M

213M

EPS

-1.9

Winstmarge

-19.869

Werknemers

528

EBITDA

31M

-39M

Aanbevelingen

By TipRanks

Aanbevelingen

Strong Buy

12 Maanden Prognose

+11.62% upside

Dividenden

By Dow Jones

Volgende Winsten

30 okt 2025

Marktinformatie

By TradingEconomics

Marktkapitalisatie

2.6B

9.5B

Vorige openingsprijs

419.34

Vorige sluitingsprijs

417.52

Nieuwssentiment

By Acuity

50%

50%

167 / 371 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Very Strong Bearish Evidence

Madrigal Pharmaceuticals Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

17 sep 2025, 23:01 UTC

Acquisities, Fusies, Overnames

Santos Confirms XRG Consortium Pulls $18.7 Billion Takeover Bid -- Update

17 sep 2025, 22:48 UTC

Acquisities, Fusies, Overnames

Santos Confirms XRG Consortium Pulls $18.7 Billion Takeover Bid

17 sep 2025, 21:59 UTC

Winsten

Cryptocurrency-Exchange Bullish Swings to Profit in First Report as Public Company

17 sep 2025, 23:44 UTC

Marktinformatie

Nikkei May Rise as Yen Weakens -- Market Talk

17 sep 2025, 23:39 UTC

Marktinformatie

Gold Rises Amid Prospects of Further Fed Rate Cuts -- Market Talk

17 sep 2025, 22:20 UTC

Acquisities, Fusies, Overnames

Santos: XRG Consortium Wouldn't Agree to Appropriate Risk Allocation Between It and Santos Shareholders

17 sep 2025, 22:20 UTC

Acquisities, Fusies, Overnames

Santos: XRG Consortium Wouldn't Agree to Acceptable Terms That Protected Value of Transaction

17 sep 2025, 22:20 UTC

Acquisities, Fusies, Overnames

Santos Had Expressed Concern to XRG Consortium About Delays in Agreeing to Scheme Implementation Agreement

17 sep 2025, 22:19 UTC

Acquisities, Fusies, Overnames

Santos: Consortium Notified Board of Decision to Withdraw Proposal on Weds Evening

17 sep 2025, 22:18 UTC

Acquisities, Fusies, Overnames

Santos Confirms XRG Consortium Has Withdrawn Takeover Proposal

17 sep 2025, 21:00 UTC

Winsten

Darden Restaurants to Report Earnings. Why the Olive Garden Parent Is Expected to Stay Strong. -- Barrons.com

17 sep 2025, 20:50 UTC

Marktinformatie

Financial Services Roundup: Market Talk

17 sep 2025, 20:50 UTC

Marktinformatie

Basic Materials Roundup: Market Talk

17 sep 2025, 19:59 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

17 sep 2025, 19:59 UTC

Marktinformatie

Treasury Yields, Dollar Rise as Fed Cuts, Powell Warns of Risks -- Market Talk

17 sep 2025, 19:07 UTC

Marktinformatie

Oil Futures Snap Three-Session Winning Streak -- Market Talk

17 sep 2025, 18:43 UTC

Marktinformatie

Treasury Yields, Dollar Reverse Course as Powell Talks to Reporters -- Market Talk

17 sep 2025, 18:38 UTC

Marktinformatie

U.S. Natural Gas Futures Mixed Ahead of Storage Data -- Market Talk

17 sep 2025, 18:20 UTC

Marktinformatie

Gold Dips After Quarter-Point Rate Cut -- Market Talk

17 sep 2025, 18:18 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

17 sep 2025, 18:18 UTC

Marktinformatie

Treasury Yields, Dollar Fall on Nearly Unanimous Fed Cut -- Market Talk

17 sep 2025, 18:14 UTC

Marktinformatie

Oil Slips Some More as Fed Makes Expected 25 Bp Rate Cut -- Market Talk

17 sep 2025, 17:59 UTC

Marktinformatie

Soyoil Takes Hit as Traders Consider EPA Proposal -- Market Talk

17 sep 2025, 17:15 UTC

Acquisities, Fusies, Overnames

Netflix 'Has Won The Streaming Wars,' Analyst Says. The Stock Is a Buy. -- Barrons.com

17 sep 2025, 17:06 UTC

Acquisities, Fusies, Overnames

Walmart Stock Heads for a Record High. The Retailer Could Become a Leader in 'Agentic' AI. -- Barrons.com

17 sep 2025, 16:51 UTC

Winsten

Correct: Exor 1H Net Loss -EUR624M

17 sep 2025, 16:34 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

17 sep 2025, 16:34 UTC

Marktinformatie

Bank of Canada Ditches Resilience Talk, Plays Up Slowing Growth -- Market Talk

17 sep 2025, 16:25 UTC

Winsten

Wolters Kluwer: July, August Saw a Slight Increase in Organic Growth Compared to 1H

17 sep 2025, 16:23 UTC

Winsten

Wolters Kluwer: Year-to-Date Performance In Line With 2025 Guidance

Peer Vergelijking

Prijswijziging

Madrigal Pharmaceuticals Inc Prognose

Koersdoel

By TipRanks

11.62% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 476.67 USD  11.62%

Hoogste 567 USD

Laagste 266 USD

Gebaseerd op 14 Wall Street-analisten die 12-maands prijsdoelen bieden voor Madrigal Pharmaceuticals Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

14 ratings

12

Buy

1

Hold

1

Sell

Technische score

By Trading Central

263.2 / 277.1Steun & Weerstand

Korte Termijn

Very Strong Bearish Evidence

Gemiddeld Termijn

Strong Bearish Evidence

Lange Termijn

Neutral Evidence

Sentiment

By Acuity

167 / 371 Rangschikking in Gezondheidszorg

Nieuwssentiment

Neutral

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Onder gemiddelde

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Madrigal Pharmaceuticals Inc

Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH. The company is headquartered in West Conshohocken, Pennsylvania.
help-icon Live chat